Latest Aethlon Medical Inc. Stories
SAN DIEGO, June 27, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) On June 12th, I issued a detailed note referencing a landmark discovery that cancer-secreted exosomes seed the spread of metastasis in melanoma patients, and added that the Aethlon Hemopurifier®, which we have been advancing with promising results in the...
SAN DIEGO, June 19, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles." The patent grants Aethlon the exclusive right...
SAN DIEGO, June 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Last week, Medical News Today reported on a cancer research discovery that reinforces the potential importance of our therapeutic endeavors. For more than a century, cancer researchers have understood that certain forms of cancer only spread to specific,...
SAN DIEGO, May 15, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO James A. Joyce will present at today's Security Research Associates (SRA) 8th Annual Growth Stock Conference. The Conference will be held at the Le Meriden Hotel in San Francisco. A live webcast of the presentation will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) and can be accessed online at: http://wsw.com/webcast/sra13/aemd/ (Photo:...
SAN DIEGO, May 8, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the presence of Hepatitis C virus (HCV) is currently undetectable in all infected patients that have been treated with the Aethlon Hemopurifier® in combination with peginterferon+ribavirin (PR) drug therapy and monitored for at least ninety days....
SAN DIEGO, May 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) On May 19th of last year, we introduced and began marketing the Aethlon ADAPT(TM) system, a technology platform that converges the capabilities of plasma membrane technology and affinity drug mechanisms. Our Aethlon ADAPT(TM) system provides a foundation to create...
SAN DIEGO, April 26, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Our Aethlon ADAPT(TM) (Adaptive Dialysis-like Affinity Platform Technology) system converges plasma membrane technology and affinity drug agents as a basis to create novel device-based therapies that are able to target the selective removal of disease-enhancing...
SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) Aethlon Medical was originally formed to advance a medical device technology that targeted the removal of harmful metals from circulation. At the time, our strategy to treat infectious disease was a mere seed of thought and we certainly didn't envision the...
SAN DIEGO, April 24, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) The gold standard for determining drug therapy benefit against infectious disease targets is to measure changes in patient viral load, otherwise known as the amount of virus that is detectable in circulation. Specific to Hepatitis C virus (HCV), the best...
SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a presentation of the Aethlon Hemopurifier® to treat Hepatitis C virus (HCV) and other infectious disease conditions will occur at the upcoming 32(nd) Annual Dialysis Conference to be held on February 26-28 at the Henry B. Gonzalez Convention...
